Premium Intelligence
The Isotope Production Map
Global Supply Chain Intelligence, Q2 2026
Facility-level production data, supply sufficiency verdicts, and strategic intelligence across 38 isotopes. Built for operators, investors, and leadership teams making capital allocation and partnership decisions in radiopharmaceuticals.
Need a team briefing or a tailored version for your board? Book a call.
Key Findings
Five structural findings that reshape how you evaluate the isotope supply chain
The Ac-225 deficit is not a capital problem
It is a physics and geology problem. Global supply stood at approximately 2 Ci per year in 2024. Each approved therapy could require 50 to 100 Ci per year. Over $1 billion in new production capacity has been announced, but timelines are measured in years, not quarters.
Diagnostic imaging depends on 1960s infrastructure
Approximately 40 million Tc-99m procedures per year depend on five ageing research reactors, three of which are over 60 years old. An unplanned HFR Petten shutdown in late 2024 caused 50-100% supply shortages globally.
De-Russification of enriched stable isotopes is succeeding
More than 95% of enriched Yb-176 (the Lu-177 precursor powering Pluvicto) was Russian-sourced until 2024. Kinectrics, ISOFLEX, and Urenco have structurally broken this bottleneck faster than the market expected.
Diversification is an illusion
Thirty-eight isotopes appear to represent a broad market. They do not. Their upstream physics, facility requirements, and precursor materials converge on a handful of single-point-of-failure nodes that create correlated fragility across apparently unrelated programmes.
Physics dictates corporate architecture
Half-life determines supply chain model. Lu-177 at 6.7 days permits centralised mega-plants. Ac-225 at 9.9 days requires regional hubs. At-211 at 7.2 hours requires near-patient production. This is not a logistics choice. It is a physics constraint.
Coverage
38 isotopes across five production modalities
Reactor-Produced
Alpha Emitters & Decay Chain
Cyclotron & Accelerator
Generator Systems
Precursors & Feedstock
Contents
What the report covers
For each isotope
Supply sufficiency verdict, production method and facilities, current and planned capacity, key developments (2024-2026), strategic implications, and fragility assessment.
Cross-cutting synthesis
Consolidated supply sufficiency dashboard, five correlated fragility clusters, winner/loser analysis by company type, and non-obvious pattern identification across the full isotope landscape.
Four-year outlook (2027-2030)
Year-by-year commissioning timelines, alpha transition pressure points, scale-up milestones, and early-warning indicators for supply disruption and opportunity.
Precursor and feedstock analysis
Ra-226, Th-229, Th-232, Yb-176, Gd-160 supply dynamics. De-Russification progress. Enriched stable isotope sourcing and the upstream dependencies most programmes overlook.
Audience
Who this is for
CEOs and COOs at isotope producers and radiopharma developers who need to understand where their supply chain is genuinely resilient and where it is not.
VP Supply Chain and VP Manufacturing leaders evaluating sourcing strategy, facility investment timing, and contingency planning across multiple isotope dependencies.
PE, VC, and sovereign wealth fund teams conducting due diligence on radiopharma investments and needing facility-level production reality rather than analyst estimates.
BD and corporate development teams evaluating partnership, licensing, or M&A targets in the isotope supply chain and needing to understand upstream constraints.
Get the report
The second publication in ProGen Search's Radiopharma Premium intelligence product line, following The State of Radiopharmaceuticals 2026.